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Abstract The effect of anandamide, an endogenous ligand for
central (CB1) and peripheral (CB2) cannabinoid receptors, was
investigated on the growth of the murine IL-6-dependent
lymphoid cell line B9 and the murine IL-3-dependent myelo-
blastic cell line FDC-P1. In conditions of low serum level,
anandamide potentiated the growth of both cytokine-dependent
cell lines. Comparison with other fatty acid cannabinoid ligands
such as (R)-methanandamide, a ligand with improved selectivity
for the CB1 receptor, or palmitylethanolamide, an endogenous
ligand for the CB2 receptor, showed a very similar effect,
suggesting that cell growth enhancement by anandamide or its
analogs could be mediated through either receptor subtype.
However, several lines of evidence indicated that this growth-
promoting effect was cannabinoid receptor-independent. First,
the potent synthetic cannabinoid agonist CP 55940, which
displays high affinity for both receptors, was inactive in this
model. Second, SR 141716A and SR 144528, which are potent
and specific antagonists of CB1 and CB2 receptors respectively,
were unable, alone or in combination, to block the anandamide-
induced effect. Third, inactivation of both receptors by pretreat-
ment of cells with pertussis toxin did not affect the potentiation
of cell growth by anandamide. These data demonstrated that
neither CB1 nor CB2 receptors were involved in the anandamide-
induced effect. Moreover, using CB2-transfected Chinese
hamster ovary cells, we demonstrated that after complete
blockade of the receptors by the specific antagonist SR
144528, anandamide was still able to strongly stimulate a
mitogen-activated protein (MAP) kinase activity, clearly in-
dicating that the endogenous cannabinoid can transduce a
mitogenic signal in the absence of available receptors. Finally,
arachidonic acid, a structurally related compound and an
important lipid messenger without known affinity for cannabi-
noid receptors, was shown to trigger MAP kinase activity and
cell growth enhancement similar to those observed with
anandamide. These findings provide clear evidence for a
functional role of anandamide in activating a signal transduction
pathway leading to cell activation and proliferation via a non-
cannabinoid receptor-mediated process.
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1. Introduction
Two G-protein-coupled receptors with seven transmem-
brane domains have been identi¢ed as cannabinoid receptors
and are referred to as CB1 and CB2 [1^4]. CB1, initially
designated the central cannabinoid receptor, is present not
only in the brain but also in peripheral tissues and leukocytes
[4^6], whereas CB2 is only present at the periphery and more
particularly on cells of hematopoietic origin [7]. Recently, it
has been shown that activation of both types of receptors led
to activation of the growth-related gene Krox-24 via the mi-
togen-activated protein (MAP) kinase cascade [8,9]. Thus, the
coupling of central and peripheral cannabinoid receptors to a
mitogenic pathway allows one to assume that cannabinoid
ligands would act as cell growth activators. In line with this
observation, we showed for the ¢rst time that synthetic can-
nabinoid ligands such as CP 55940 and WIN 55212-2 behave
as CB2-speci¢c growth-activating cofactors for human B-lym-
phocytes primed via stimulation of B-cell antigen receptor or
CD-40 receptor [10,11].
In this study, we focused on the e¡ect of the natural endog-
enous ligand anandamide [12] on the growth of two cytokine-
dependent cell lines of di¡erent hematopoietic lineages. Anan-
damide displays speci¢c binding to CB1 and CB2 receptors
and induces pleiotropic e¡ects: anandamide released from
neurons is a messenger modulating synaptic functions [13],
produced by macrophages it is a mediator of hemorrhagic
hypotension [14] ; it is also considered a growth stimulator
for hematopoietic cells [15] and has been shown to inhibit
lymphocyte proliferation and tumor necrosis factor K
(TNFK) production [16,17]. Anandamide has been detected
in di¡erent regions of the central nervous system and also in
peripheral tissues such as spleen, heart and skin [18]. The wide
distribution of anandamide and its broad range of activity
raise the question whether this endogenous mediator exerts
its e¡ects only through the two cannabinoid receptors char-
acterized so far. The relatively low a⁄nity of anandamide
for both CB1 and CB2 receptors, its presence at signi¢cant
levels in tissues such as heart known to express few if any
cannabinoid receptors [7,18] and the demonstration of canna-
binoid receptor-independent e¡ects of anandamide [19]
suggest the existence of other binding structures. Moreover,
its lipid character and ability to permeate membranes lead one
to suspect that direct, non-receptor-mediated e¡ects could
occur.
In this study, using the selective antagonists SR 141716
(CB1) and SR 144528 (CB2) [11,20], we demonstrated that
anandamide and other fatty acid cannabinoids stimulate cell
growth via a cannabinoid receptor-independent process and
likely through direct activation of a MAP kinase pathway.
This work is a signi¢cant example of the dual mechanism of
action of endogenous fatty acid cannabinoids which represent
a new class of lipid messengers also able to deliver intracellu-
lar messages by bypassing their receptors.
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2. Materials and methods
2.1. Reagents
CP 55940 was obtained from P¢zer. Anandamide, (R)-methan-
andamide, palmitylethanolamide, arachidonic acid and pertussis toxin
were purchased from Biomol Research Laboratories (Plymouth Meet-
ing, USA). The CB1 antagonist SR 141716A [20] and the CB2 antag-
onist SR 144528 [11] were synthesized at Sano¢ Recherche (Montpel-
lier, France). Drugs were dissolved at 1032 M in ethanol and stored at
380‡C. Human rIL-6 was produced in Escherichia coli at Sano¢ Re-
cherche, the speci¢c activity was 5U109 U/mg. Murine recombinant
IL-3 was obtained from Genzyme (Cergy, France).
2.2. Cell lines
The murine IL-6-dependent hybridoma cell line B9 [21] was grown
in RPMI medium supplemented with 10% fetal calf serum, 5U1035 M
L-mercaptoethanol, 100 U/ml penicillin, 100 Wg/ml streptomycin
and 50 U/ml IL-6. The murine IL-3-dependent myeloblastic cell line
FDC-P1 [22] was grown in IMDM medium supplemented with 10%
horse serum, 100 U/ml penicillin, 100 Wg/ml streptomycin, 1 ng/ml IL-
3.
2.3. Detection of CB1 and CB2 receptor mRNAs
The expression of mRNAs for L2-microglobulin, CB1 and CB2
receptors was examined by reverse transcription coupled to the
polymerase chain reaction (RT-PCR) as previously described [23].
mRNA puri¢cation from B9 and FDCP1 cells followed by conversion
to ¢rst strand cDNA was performed with the PolyATract Series 9600
mRNA Isolation System with cDNA Synthesis Reagents (Promega,
CharbonieØres, France) according to the manufacturer’s instructions.
DNA ampli¢cations were carried out in PCR bu¡er (Perkin Elmer-
Cetus, Saint-Quentin, France) containing 6 Wl of cDNA solution with
0.1 mM dNTP (Pharmacia Biotech, Orsay, France), 0.25 WM of each
primer and 0.5 U Taq polymerase (Perkin Elmer-Cetus) in a ¢nal
volume of 20 Wl. The mixture was ampli¢ed with the GeneAmp
PCR 9600 Thermal cycler (Perkin Elmer-Cetus). The thermal reaction
pro¢le consisted of a denaturation step at 95‡C for 20 s, annealing at
60‡C for 30 s and an extension step at 75‡C for 20 s. Reaction was
performed for 35 cycles. After PCR, 5 Wl loading bu¡er (Novex, San
Diego, CA, USA) was mixed with 10 Wl PCR products and separated
by electrophoresis on 3% agarose gel in the presence of ethidium
bromide with 123 bp DNA markers (Gibco, Eragny, France) as mo-
lecular weight controls.
The speci¢c mouse oligonucleotides used were purchased from Gen-
set (Paris, France). All the primers were made of 18^20-residue oligo-
nucleotides with 50% G+C content and lacking 3P complementary
between primer pairs. L2-Microglobulin primers: sense 5P-TGAC-
CGGCTTGTATGCTATC-3P ; antisense 5P-CAGTGTGAGCCAG-
GATATAG-3P. CB1 primers: sense 5P-TACCATCACCACAGACC-
TCC-3P ; antisense 5P-TGACACATAGCACCAGCAG-3P. CB2 pri-
mers: sense 5P-GCCTGCAACTTTGTCATC-3P, antisense 5P-GG-
CTTTCCAGAGGACATAC-3P. The expected size of the amplicons
were 222 bp for L2-microglobulin, 383 bp for CB1 receptor and 386
bp for CB2 receptor.
2.4. Treatment of cells, evaluation of DNA synthesis and expression
of results
Five thousand B9 cells, in a total volume of 200 Wl serum-free
medium, were cultured in triplicate in 96-well microtiter trays for 24
h in the presence of the indicated concentrations of IL-6, cannabinoid
agonists or antagonists. Ten thousand FDC-P1 cells in medium con-
taining 1% horse serum and the indicated concentrations of IL-3 were
similarly treated for 48 h. Cells were used in the exponential phase of
growth and were serum-deprived at the beginning of the experiment.
DNA synthesis was determined by pulsing the cells with 1 WCi/well of
[3H]thymidine for the last 4 h of the culture period. Cells were then
harvested on nitrocellulose ¢lters using a Harvester 96 (Tomtec) and
radioactivity counted in a microscintillation counter (Microbeta Tri-
lux, Wallac).
Experiments were done at least twice and results were expressed as
mean [3H]thymidine uptake (cpm þ S.D.) in most of the experiments.
The e¡ect of cannabinoid receptor antagonists or pertussis toxin
(Figs. 4 and 5) was evaluated by comparing the range of stimulation
induced by anandamide in the presence or in the absence of these
agents and expressed as % increase of DNA synthesis
% increase  cpm anandamide  antagonist or
PTX=cpm control  antagonist or PTXU100
2.5. Expression of CB2 receptors in Chinese hamster ovary (CHO)
cells and culture conditions
CB2 cDNA was obtained by screening a cDNA library from the
human promonocytic cell line U937 with a horseradish peroxidase-
labeled CB2-speci¢c oligonucleotide (5P-CTCACACACTTCTTC-
CAGTG), followed by detection using the ECL system (Amersham).
Human CB2 coding region was ampli¢ed by PCR using the primer
pair 5P- CCACACAAGCTTGCCACCATGGAGGAATGCTGGG-
TG and 5P- CCACTCGGATCCTCAGCAATCAGAGAGGTCTAG
and inserted into the p658 plasmid, an expression vector derived from
p7055 in which the IL-2 coding sequence was replaced by a polylinker
[8]. The sequence of the insert in the expression vector was veri¢ed
before transfection into CHO dihydrofolate-reductase-negative cells
by the Ca3(PO4)2 precipitation method [9].
Cells stably transfected with CB2 were grown in minimal essential
medium supplemented with 10% dialyzed fetal calf serum, 2 mM
glutamine, 40 Wg/ml L-proline, 1% anti-PPLO agent, 1 mM sodium
pyruvate and 5 Wg/ml gentamicin. Wild type (wt) CHO cells were
grown in the same medium supplemented with 10% fetal calf serum.
2.6. Analysis of MAP kinase activity
MAP kinase activity was measured as described [9]. Brie£y, wt and
CB2-CHO cells grown to 80% con£uence were maintained in culture
medium without serum for 24 h prior to the addition of ligands. Cells
were pretreated with the CB2 antagonist SR 144528 (500 nM) for
2 min before treatment with the indicated concentrations of anand-
amide for another 10 min at 37‡C. Cells were then washed at 4‡C with
0.5 ml bu¡er A (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM
ethyleneglycol-bis-(L-aminoethyl ether)-N,N,NP,N-tetraacetic acid,
1 mM Na3VO4) and lysed for 15 min in bu¡er A supplemented
with 1% Triton X-100, 10 Wg/ml aprotinin, 10 Wg/ml leupeptin,
1 mM dithiothreitol and 1 mM phenylmethylsulfonyl £uoride. Solu-
bilized cell extracts were then clari¢ed by centrifugation at 14 000Ug
for 15 min at 4‡C. Aliquots (15 Wl) were removed and stored at 380‡C
until use. Phosphorylation assays were carried out at 30‡C for 30 min
(linear assay conditions) with Q-33P-ATP using the Biotrack p42/p44
MAP kinase enzyme system (Amersham). The radioactivity incorpo-
rated was determined by liquid scintillation counting and expressed as
percent increase over basal level. The background radioactivity was
less than 10% of the total radioactivity incorporated in non-treated
cells.
3. Results
3.1. CB1 and CB2 receptor mRNAs expression in murine
hematopoietic cell lines
Using semi-quantitative RT-PCR, we compared the levels
of transcripts for CB1 and CB2 receptors in B9 and FDC-P1
cell lines. As shown in Fig. 1A, B9 cells displayed equivalent
amounts of CB1 and CB2 mRNAs. B9 is a mouse-rat hetero-
hybrid lymphoid cell line [21] and RT-PCR analysis using
speci¢c rat primers instead of mouse primers as in Fig. 1
gave similar results (not shown). In FDC-P1 cells (Fig. 1B),
CB2 and CB1 mRNAs were also present at similar levels.
Thus, the expression of transcripts for the ‘central’ and the
peripheral cannabinoid receptors was obvious on both cell
lines and provided a molecular basis for the evaluation of
the potential e¡ects of cannabinoid ligands on the activation
of these cells.
3.2. E¡ect of anandamide on the proliferative response
The e¡ect of anandamide, a natural endogenous ligand of
cannabinoid receptors [12], was ¢rst examined at optimal con-
centrations of 0.5^1 WM on B9 and FDC-P1 cells cultured
with increasing amounts of IL-6 and IL-3 respectively (Fig.
2A,C). In the absence of any growth factor, anandamide by
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itself did not signi¢cantly in£uence the DNA synthesis of the
cytokine-dependent cell lines. However, anandamide greatly
enhanced the rate of DNA synthesis of both cell lines, by a
factor of 2^3, when the respective growth factors were present
in the culture medium. The stimulating e¡ect of anandamide
was concentration-dependent with a maximal activation ob-
tained at 0.5^1 WM for B9 cells and 0.25^0.5 WM for FDC-P1
cells costimulated with either 50 U/ml IL-6 or 50 Ng/ml IL-3
respectively (Fig. 2B,D). In the conditions depicted in Fig. 2B,
the addition of 1 WM anandamide increased the cell number
by a factor 2.2 (9300 þ 52 B9 cells in treated wells vs.
4200 þ 30 in non-treated control wells), indicating that the
enhancement of DNA synthesis was related to a proliferative
response.
This synergistic response induced by anandamide was ob-
served in serum-free medium for B9 cells or in very low serum
concentration (1%) for FDC-P1 cells and all the experiments
reported thereafter were done under the same conditions. In-
deed, the e¡ect of anandamide decreased progressively with
higher serum concentrations and was totally abolished when
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Fig. 4. Absence of antagonistic e¡ect of the cannabinoid receptor
antagonists SR 141716 and SR 144528. B9 cells costimulated with
50 U/ml IL-6 and 0.5 WM anandamide were treated for 24 h with
the indicated concentrations of the CB1 or CB2 antagonists SR
141716 (A) and SR 144528 (B) respectively or a mixture of both
(C). Cells were also identically treated with the ‘inactive’ CB1-CB2
agonist CP 55940 (D). Data are expressed as percent increase of
DNA synthesis as indicated in Section 2.
Fig. 3. Comparison of anandamide with other fatty acid analogs
and with a synthetic cannabinoid ligand. B9 cells were stimulated in
serum-free medium for 24 h with 50 U/ml IL-6 and the indicated
concentrations of the fatty acid cannabinoids anandamide, (R)-
methanandamide, palmitylethanolamide (A) or with the synthetic
cannabinoid CP 55940 (B). Thymidine uptake was measured as in
Fig. 2.
Fig. 2. E¡ect of anandamide on thymidine uptake in two hemato-
poietic cell lines. B9 cells were costimulated in serum-free medium
with increasing amounts of IL-6 in the presence or in the absence
of 1 WM anandamide (A) or with 50 U/ml IL-6 and the indicated
concentrations of anandamide (B) for 24 h. FDC-P1 cells were cul-
tured for 48 h in medium supplemented with 1% horse serum with
increasing concentrations of IL-3 with and without 0.5 WM anand-
amide (C) or with a constant concentration (50 pg/ml) of IL-3 and
varying concentrations of anandamide (D). [3H]Thymidine uptake
(cpm þ S.D.) was measured in triplicate as indicated in Section 2.
Fig. 1. Cannabinoid receptor gene expression in B9 and FDC-P1
cells. PCR products were obtained after ampli¢cation of mRNA-de-
rived cDNA from murine B9 cells (A) and murine FDC-P1 cells (B)
using mouse CB1- and CB2-speci¢c primers. Negative control was
performed with no cDNA. Internal control was obtained by PCR
of L2-microglobulin gene.
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the optimal 10% concentration required for culture mainte-
nance was used (data not shown).
3.3. Comparison of anandamide with other fatty acid analogs
and with a synthetic cannabinoid ligand
Since anandamide binds both CB1 and CB2 receptors, in a
¢rst attempt to determine which receptor subtype may be
involved, we compared anandamide with two other fatty
acid ligands displaying better selectivity. Fig. 3A shows that
(R)-methanandamide, an analog of anandamide with higher
selectivity for CB1 [24], and palmitylethanolamide, an endog-
enous agonist for CB2 [25], similarly increased the rate of
DNA synthesis in the IL-6-costimulated B9 cells within the
same range of concentrations as that observed with anand-
amide (EC50W0.3 WM for the three compounds). These data
suggested that the two types of receptors, simultaneously
present on the cells, were equally e⁄cient in transducing a
proliferative signal.
If so, a potent agonist, such as the reference synthetic can-
nabinoid ligand CP 55940, known to bind and activate CB1
and CB2 with an equal potency and more e⁄ciently than
anandamide [3,26], would induce a proliferative signal of at
least the same magnitude. As shown in Fig. 3B and in con-
trast to what was expected, CP 55940 failed to demonstrate
any e¡ect on cell activation when tested in the same condi-
tions and over the same range of concentrations as anand-
amide.
3.4. Cannabinoid receptor speci¢city studies
The absence of stimulation by the potent synthetic ligand
CP 55940 was intriguing enough to raise the question of the
receptor speci¢city of the anandamide-induced e¡ect. In a ¢rst
attempt to elucidate this question, the antagonists SR 141716
and SR 144528, speci¢c for CB1 and CB2 receptors respec-
tively [11,20], were used alone or in combination with an-
andamide. Moreover, since the CB1/CB2 ligand CP 55940
was ine¡ective, this compound was also tested itself as an
‘anandamide blocker’. Data presented in Fig. 4 showed that
neither the respective speci¢c antagonists alone or in combi-
nation nor the inactive bispeci¢c agonist tested over a wide
range of concentrations were able to inhibit even partially the
DNA synthesis stimulation induced by 0.5 WM anandamide.
These results represented the ¢rst strong indication that the
anandamide-induced e¡ect was not mediated through CB1 or
CB2 receptors.
Cannabinoid receptors are coupled to a heterotrimeric Gi-
protein which can be selectively inactivated by pretreatment
with PTX [8^10]. We therefore compared the growth-enhanc-
ing e¡ect of anandamide in the absence or in the presence of
PTX. Fig. 5 shows that the anandamide-driven cell growth
enhancement was not a¡ected by the presence of the toxin,
thus reinforcing the notion of a cannabinoid receptor-inde-
pendent phenomenon.
3.5. Anandamide induces a non-receptor-mediated signal
transduction
A cell line transfected with only one cannabinoid receptor
subtype which can be speci¢cally blocked by the correspond-
ing antagonist ligand represented a very helpful tool to ex-
plore the respective pathways used by anandamide. Synthetic
cannabinoid agonists mediate receptor-dependent activation
of MAP kinase [8,9]. A similar investigation was carried out
with anandamide in comparison with CP 55940. Fig. 6A
shows that anandamide stimulated a MAP kinase activity in
CB2-transfected CHO similarly to CP 55940. The optimal
e¡ect was observed at concentrations of 100^1000 nM which
corresponded to those required for cell growth enhancement
while 100-fold lower concentrations were needed for CP
55940. Remarkably, whereas the full blockade of cannabinoid
receptors by SR 144528 induced a complete inhibition of the
CP 55940-driven e¡ect, anandamide in the same conditions
was still able to stimulate a strong MAP kinase response
which represented about 50% of the total activity. Accord-
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Fig. 6. Anandamide stimulation of MAP kinase. CB2-CHO cells
were treated for 10 min with the indicated concentrations of CP
55940 or anandamide in the presence or in the absence of the CB2
antagonist SR 144528 added at 0.5 WM 2 min before (A). The ef-
fects of CP 55940 (3 nM), anandamide and arachidonic acid (both
1 WM) were compared in CB2-CHO cells (B) and wt CHO cells (C)
with and without 0.5 WM SR 144528. MAP kinase activities were
measured in cell lysates as indicated in Section 2.
Fig. 5. Absence of e¡ect of pertussis toxin (PTX) on anandamide-
induced growth enhancement. B9 cells stimulated in serum-free me-
dium with 50 U/ml IL-6 were preincubated 5 h with 50 ng/ml PTX
and then treated with the indicated concentrations of anandamide
for 24 h. Data are expressed as percent increase of DNA synthesis
as indicated in Section 2.
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ingly, in control wt CHO cells, anandamide and CP 55940, at
the optimal concentrations of 1 WM and 3 nM respectively,
displayed completely di¡erent e¡ects: while anandamide
stimulated a signi¢cant MAP kinase activity which as ex-
pected was not a¡ected by the cannabinoid receptor antago-
nist SR 144528, the speci¢c ligand CP 55940 was totally in-
active (Fig. 6C). These data demonstrated that anandamide
exhibited the property of transducing a similar transduction
signal through both receptor- and non-receptor-mediated
mechanisms.
3.6. Comparison of anandamide and arachidonic acid
The e¡ect of anandamide, which is composed of arachi-
donic acid and ethanolamine coupled through an amide link-
age (arachidonic acid N-[hydroxyethyl]amide), was directly
compared to that of arachidonic acid itself, an important
cellular lipid mediator. Data depicted in Fig. 7 show similar
concentration-dependent growth-promoting e¡ects of arachi-
donic acid and anandamide in B9 cells (EC50W0.3^0.4 WM
for both compounds). This identical e¡ect was probably medi-
ated via a similar pathway since at optimal concentrations
both agents were able to activate a receptor-independent
MAP kinase cascade in CB2-transfected and control wt
CHO cells as well (Fig. 6B,C).
4. Discussion
In this study, we showed that anandamide, an endogenous
ligand for central (CB1) and peripheral (CB2) cannabinoid
receptors [12], enhanced the growth of two cytokine-depend-
ent murine hematopoietic cell lines, the IL-3-dependent mye-
loblastic cells FDC-P1 and the IL-6-dependent lymphoid cells
B9, in condition of low serum level. Our results are in line
with a previous study [15] which demonstrated in similar con-
ditions the same growth-inducing e¡ect for anandamide in
di¡erent cytokine-dependent myeloid and erythroid cell lines.
This suggested a general synergistic e¡ect of anandamide
whatever the hematopoietic lineages and the cytokines re-
quired for their growth. Besides, this e¡ect was not limited
to anandamide but was extended to other fatty acid cannabi-
noid ligands such as the CB1-selective agonist (R)-methan-
andamide [24] and the CB2 agonist palmitylethanolamide
[25]. However, the equipotent (CB1 and CB2) cannabinoid
ligand CP 55940, which binds cannabinoid receptors with a
100-fold higher potency than anandamide [26], was inactive in
these models (this study, [15]). The lack of e¡ect of an agonist
which in other models activates biological functions of can-
nabinoid receptors with higher e⁄ciency than anandamide
[7,8,10,11,27] was a surprising datum which led us to deter-
mine whether the anandamide-induced e¡ect described in this
model was a speci¢c cannabinoid receptor-mediated process.
It came out from receptor speci¢city studies that neither the
CB1 antagonist SR 141716A nor the CB2 antagonist SR
144528, which bind and saturate their respective receptors at
nanomolar concentrations [11,20], was able alone or in asso-
ciation to inhibit the e¡ect of anandamide. Moreover, the
‘non-inducer’ CB1-CB2 agonist CP 55940, which was thus
used as an ‘antagonist’, also failed to inhibit the e¡ect of
anandamide. These results represented the ¢rst evidence for
a non-CB1- or -CB2-mediated process.
However, though two Gi-protein-coupled cannabinoid re-
ceptors have been described so far, the presence of other Gi-
protein-coupled receptors which could account for the e¡ect
of anandamide cannot be totally excluded. Nonetheless, the
absence of e¡ect of PTX, a Go-Gi-protein inhibitor, on the
enhancing property of anandamide allowed us to rule out
such an hypothesis. Therefore, considering these results, we
could assume not only that the growth-promoting e¡ect in-
duced by anandamide was CB1 or CB2 receptor-independent,
but also that other putative Go-Gi-linked receptors were not
involved any more. However, the involvement of an as yet
unidenti¢ed PTX-independent cannabinoid receptor cannot
be totally excluded.
Our ¢ndings are in contrast to the study cited above [15]
where the authors, in a similar model of cytokine-dependent
cell lines, described the anandamide e¡ect as a speci¢c CB2
receptor-mediated process. Their assertion was based on the
fact that one CB2-positive hematopoietic cell line which was
non-responsive to anandamide became sensitive to its stimu-
lating e¡ect after overexpression of CB2 receptors by trans-
fection. However, it cannot be excluded that the transfection
induced changes or perturbations making the cells more sen-
sitive to a ‘non-speci¢c’ e¡ect of anandamide. Alternatively,
overexpression of a high number of CB2 receptors may arti-
¢cially guarantee speci¢city to some extent in these particular
transfected cells but this does not preclude the possibility of a
‘non-speci¢c’ e¡ect in normal non-transfected cells. Several
lacking controls should have been done to ascertain the role
of CB2 receptors in their models : a study of CB1-transfected
counterparts, use of PTX to provide demonstration of a role
of the Gi-linked cannabinoid receptors, receptor blockade by
synthetic agonists which were also reported to be inactive,
comparison with hematopoietic cell lines which were reported
to be double negative CB23/CB13. In the absence of relevant
controls, the CB2 speci¢city of anandamide in this model
remains speculative.
It has been shown that stimulation of cannabinoid recep-
tors by synthetic ligands induces a MAP kinase signaling
pathway [8,9]. In this study, using the model of CB2-trans-
fected CHO cells, we reported a similar stimulation of MAP
kinase with the natural endogenous cannabinoid anandamide
in the range of concentrations required for cell growth en-
hancement. Transfected CHO cells therefore represent a
very useful tool and an additional model to go deeper into
the question of the cannabinoid receptor speci¢city of anand-
amide. This model allowed us to demonstrate that when cells
were exposed to saturating concentrations of the speci¢c an-
tagonist SR 144528 and thus in absence of available receptors,
anandamide was still able to exhibit a MAP kinase activity
FEBS 20042 3-4-98
Fig. 7. Comparison of anandamide and arachidonic acid on growth-
promoting e¡ect. B9 cells were costimulated with 50 U/ml IL-6 and
the indicated concentrations of anandamide or arachidonic acid.
After a 24 h incubation, the thymidine incorporation was measured
as in Fig. 2.
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which represented 50% of the total activity. This ability of
anandamide to elicit a non-receptor-mediated MAP kinase
activation was further con¢rmed in control wt CHO cells.
These data evidenced the dual function of anandamide able
to induce signal transduction through both receptor- and non-
receptor-mediated pathways. In contrast, the e¡ect of the
reference compound CP 55940 was totally abolished by SR
144528 in CB2-CHO cells, indicating for this ligand a strictly
speci¢c receptor-related process also attested by an absence of
e¡ect in wt CHO cells. In addition, these data could imply
that the growth-enhancing e¡ect observed with anandamide
on hematopoietic cells could be mediated through a receptor-
independent activation of a MAP kinase cascade. One hy-
pothesis to explain the synergistic e¡ect of anandamide with
cytokine growth factors could be that activation in parallel of
two di¡erent pathways (possibly MAP kinase and JAK/STAT
kinase) leads to enhanced cell cycling. Conversely, the absence
of a growth-promoting e¡ect of the speci¢c cannabinoid re-
ceptor ligand CP 55940 in hematopoietic cells would likely
mean that, in these cells, CB2 receptors are not functionally
linked to a MAP kinase pathway or that CB2 receptors mod-
ulate intracellular events downstream of the MAP kinase ac-
tivation that are di¡erent from those triggered directly by
anandamide in a receptor-independent way. Further investi-
gations are needed to elucidate this point.
Nevertheless, the hypothesis that anandamide stimulates
cell growth via a receptor-independent MAP kinase activation
is relevant with the observation that anandamide, at similar
concentrations as those used in this study, induces a non-re-
ceptor-mediated release of arachidonic acid via stimulation of
phospholipase A2 (PLA2) [19]. Arachidonic acid released after
activation of membrane-associated PLA2 represents an impor-
tant lipid messenger activating di¡erent subgroups of MAP
kinase such as p42MAPK and p44MAPK (ERK) via the eicosa-
noid cascade or C-jun N-terminal kinase (JNK) via the acti-
vation of NADPH oxidase and independently of a down-
stream eicosanoid biosynthesis [28]. These data added to the
fact that arachidonic acid acts as an important mediator in-
volved in cellular proliferation and mitogenesis [28^30] led us
to compare the arachidonic acid derivative, anandamide, with
arachidonic acid itself. We found an identical stimulatory ef-
fect of both compounds on cell growth, within the same range
of concentrations and to the same extent, reinforcing the no-
tion of a direct activation without any receptor requirement.
Accordingly, we also observed a very similar activation of
MAP kinase by both agents in control and CB2-transfected
CHO cells, strengthening the assumption that a receptor-in-
dependent activation of a MAP kinase pathway was involved.
Two hypotheses can be put forward to explain the similarity
between anandamide and arachidonic acid. First, the lipo-
philic anandamide may directly stimulate membrane-bound
PLA2 and arachidonic acid production as already reported
[19] which in turn activates cell growth. Second, hydrolytic
degradation of the unstable anandamide into arachidonic
acid may represent another possibility. In any case, fatty
acid cannabinoids, in addition to their receptor-mediated ac-
tions largely documented in the literature, are directly able to
activate an arachidonic acid-like signaling cascade leading to
cell activation. Interestingly, it has been recently reported that
arachidonic acid stimulates downstream a c-fos serum re-
sponse element in ¢broblasts [31]. If this result can be extrapo-
lated to hematopoietic cells, it would explain why cell activa-
tion by anandamide (this study, [15]) or by arachidonic acid
(this study) was only revealed in serum-starved cells.
Whatever the precise mechanism underlying the non-recep-
tor-mediated e¡ects of endogenous fatty acid cannabinoids,
we clearly demonstrate for the ¢rst time in this study that
these messengers were able to directly activate a fundamental
biological process such as cell growth by bypassing their re-
ceptors. Moreover, evaluation of cannabinoid-induced biolog-
ical e¡ects imposes that steps must be taken to discriminate
between receptor- and non-receptor-mediated actions. With
regard to the totally di¡erent cellular events that can be elic-
ited by either method, this represents a fundamental aspect for
the understanding and the deciphering of the physiological
role of endogenous cannabinoids.
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